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Abstract 
Dissolution enhancement of poorly water soluble drugs is a major challenge in pharmaceutical 
industry. The aim of this study is to fabricate curcumin nanoparticles by antisolvent crystallization 
in the presence of PVP-K30 or HPMC with various concentrations as a stabilizer. The effect of 
high pressure homogenization on properties of curcumin particles is also investigated in this study. 
The antisolvent crystallization method followed by freeze drying (CRS-FD) and also antisolvent 
crystallization and high pressure homogenization followed by freeze drying (HPH-FD) were 
employed to modify curcumin particles. Physical mixtures of the drug and additives were also 
prepared for comparison purposes. The solid state analysis (DSC, XRPD and FT-IR studies), 
particle size measurement, morphological analysis, saturation solubility and dissolution behavior 
of the samples were investigated. The curcumin crystallized without using stabilizer produced 
polymorph 2 curcumin with lower crystallinity and higher solubility. The samples obtained in the 
presence of stabilizers showed higher solubility compared to its physical mixtures counterpart. It 
was found that the stabilizers used in the current study were capable of inhibiting the crystal growth 
of particles during crystallization. High pressure homogenizer method generated smaller particles 
compared to those samples that were not subjected to high pressure homogenizer (for example, 
2748 nm for 5% PVP CRS-FD sample and 706 nm for 5% PVP HPH-FD sample). Particles 
obtained via HPH showed better solubility and dissolution rate compared to those samples that 
HPH was not employed (for example, the saturated solubility of 25% PVP CRS-FD sample was 
near 2 µg/ml while this amount was approximately 4.3 µg/ml for 25% HPH-FD sample. The effect 
of high pressure homogenization on dissolution rate is more pronounced for samples with lower 
stabilizer ratio. The samples prepared with high pressure homogenizer using 50% PVP showed 
25-fold higher solubility compared to untreated curcumin. Generally, it can be concluded that the 
method of preparation, selection of suitable stabilizer and concentration of stabilizer play a critical 
role on particle size and dissolution rate of curcumin.  
Keywords: curcumin, antisolvent crystallization, dissolution rate, high pressure homogenization 
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1. Introduction 
Formulation of poorly water soluble drugs is a major challenge in the pharmaceutical industry. 
There are many strategies which have been used before for improving the solubility and dissolution 
rate of poorly water soluble drugs [1]. Reduction of particle size to nanoscale is the most favorable 
way which has been used in last decades. According to Noyes-Whitney equation, reducing the 
particle size results in higher surface area and hence higher dissolution rate. Beside that reduction 
in the particle size to the nanometer size increases the saturation solubility due to the Ostwald-
Freundlich equation which is normally not obtained when the particles are micronized [2, 3].  
In general, preparation of nanoparticles can be reached by two strategies; bottom up and top down 
methods [2]. In the pharmaceutical industry nanoparticles are mainly produced by top down 
strategy [4]. High pressure homogenization (HPH) and media milling are the most favorable 
methods to produce these nanoscale materials [3, 5]. In these methods the particles break down to 
nanoscale size by attrition, collision and sometimes cavitation especially for HPH process. 
However, these methods suffer from some disadvantages. In most of the time, the preparation of 
nanoparticles with these methods need high energy input, long time processing, wide particle size 
distribution and probability of metal consumption [4, 6]. In contrast to top down procedure, in 
bottom up strategy nanoparticles can be obtained by molecular arrangements. One of the simplest 
and cost effective methods for preparation of nanoparticles via this strategy is antisolvent 
crystallization technique. In this method, simply the solubilized drug in an organic solvent is added 
to an antisolvent that is miscible with the first solvent. In most cases, water has been used as an 
antisolvent. The precipitated drug could be separated by filtration, spray drying or freeze drying 
techniques. This method does not need any expensive equipment, high energy input or long 
processing time. In addition, particle engineering and crystal manipulation could be performed by 
this method [7, 8]. In addition, supercritical fluid techniques have been used for producing small 
and nanosized particles [9-11]. However, preventing the crystal growth is the biggest problem in 
this process. In order to tackle this problem, the addition of stabilizers could inhibit crystal growth 
of drugs by adsorbing to the surface of obtained crystals. Various stabilizers have been used for 
this purpose [12]. As in most cases these stabilizers are hydrophilic, therefore, the presence of 
these stabilizers could also be beneficial in order to improve the solubility properties of poorly 
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water soluble APIs. However, it has been shown that different stabilizers do not exhibit the same 
effect on crystal growth of the crystals during the crystallization process [12].   
Although the antisolvent crystallization could engineer the nanoparticles by molecular 
arrangement, however, as described before it suffered from crystal growth [7]. In last decade, a 
combination process has been used in many studies such as Nanoedge® technology (used by Baxter 
Inc.) where precipitation was coupled with HPH. In this process antisolvent crystallization 
combined with high pressure homogenization during crystallization or after it. In this method the 
aggregated particles could be broken down to lower particle size. In addition, amorphous or 
unstable particles obtained during antisolvent crystallization could convert to more stable form 
after HPH process [5, 13]. This combination process has been used for different poorly water 
soluble drugs like itraconazole [14], isradipine [15] and celecoxib [16, 17].  
Curcumin is a hydrophobic phenolic compound which is extracted from the rhizome of turmeric. 
This substance showed some various pharmacological activities such as anticancer, antioxidant, 
anti-inflammatory, and antimicrobial properties ,however, due to its poor water solubility (11 
ng/ml at pH 5.0) its oral bioavailability is limited and incomplete [18]. Various attempts have been 
used in the past to overcome this problem. Reducing the particle size [19-21], preparation of solid 
dispersion [22, 23], solid lipid nanoparticles [24], nanomicelles [25, 26], and using cyclodextrins 
[27] are some examples which have been explored. The aim of this study was to prepare curcumin 
nanoparticles with a better dissolution behavior. Antisolvent crystallization in the presence of 
HPMC and PVP at various concentrations as a stabilizer has been used in this study. In addition, 
the effect of high pressure homogenization process was employed to optimize the physiochemical 
properties of curcumin particles.  
 
2. Materials and methods 
2.1. Materials 
Curcumin was purchased from Mitushi Biopharma, India (pharmaceutical grade). PVP-K30 and 
HPMC E3 were purchased from Sigma-Aldrich, Germany (Pharmaceutical grade). Acetone and 
sodium dodecyl sulfate (SDS) were obtained from Merck (analytical grade). 
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2.2. Methods 
2.2.1. Preparation of CUR:HPMC and CUR:PVP freeze dried nanoparticles precipitated by 
antisolvent crystallization method (CRS-FD) 
1 gram of curcumin was dissolve in 20 ml of acetone. Then the acetone solution containing 
curcumin was added to the 200 ml aqueous solution contain 0, 50, 100, 250 and 500 mg stabilizer 
(PVP or HPMC) at a rate of 5 ml/min using a burette. The aqueous solution was kept under stirring 
condition at 600 rpm and the temperature was kept at 25 °C during precipitation. The final 
concentration of each suspension was 1:0, 20:1, 10:1, 4:1 or 2:1 curcumin:polymer respectively. 
The final suspension was immediately freeze dried at -70 °C followed by freeze drying (Martin 
Christ freeze dryer, Germany) for 48 h. Each crystallization experiment was performed in 
triplicate. 
 
2.2.2. Preparation of CUR:HPMC and CUR:PVP freeze dried nanoparticles precipitated by 
antisolvent crystallization method followed by high pressure homogenizer (HPH-FD) 
Half part of the obtained suspenstions from previous method (CRS) were further homogenized 
with A FBF laboratory high pressure homogenizer (Italy). The applied pressure was set at 500 bars 
for 5 cycles (first step) and 1000 bars for 10 cycles (final step). The final suspension obtained after 
applying HPH was immediately freeze- dried at -70 °C for 48 h. Each experiment was performed 
at least three times.  
 
2.2.3. Preparation of physical mixtures of drug carrier (PM) 
Physical mixtures of CUR and stabilizer were prepared as the same ratios as the treated 
formulations r comparison purposes. To this end, CUR, HPMC or PVP were sieved to get particle 
size fractions of less than 250 µm followed by mixing of CUR with HPMC or PVP using a spatula 
for 2 min. The formulations were kept in well-tight containers until further use. 
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2.2.4. Morphological analysis 
Optical microscope (Olympus BX-60, Japan) was used to observe particles formation during the 
manufacturing process before freeze drying. In addition, SEM images of the freeze-dried particles 
were obtained using a scanning electron microscope (Philips X series, Netherlands) with an 
acceleration voltage of20 kV.  
2.2.5. Particle size measurement 
In order to measure the particle size of particles obtained via CRS and HPH process a nano-
zetasizer (Malvern, UK) was used. To do this end, the obtained nanosuspension was diluted with 
deionized water to reach the concentration of 1mg/ml. In the case of freeze dried samples this 
concentration was prepared by dispersing the powders in deionized water using ultrasound water 
bath (2 minutes).  The measurements were carried out in triplicate and their mean and standard 
deviation of Z-average size and zeta potential of the particles were calculated. 
  
2.2.6. Saturation solubility study 
Saturation solubility of untreated CUR, PMs and freeze dried samples obtained via different 
methods were determined according to the method published elsewhere [28]. An excess amount 
of CUR (2 mg) was dispersed in 20 ml double-distilled water in a beaker stirring at 200 rpm at 25 
°C for 48 h. The suspensions were then filtered through a 0.22 µm filter (MS® Nylon Syringe 
Filter) and then the concentration of solution was measured by spectrophotometer at a wavelength 
of 426 nm (Shimadzu, Japan).  
 
2.2.7. Differential scanning calorimetry (DSC) 
Thermal analysis of selected freeze dried samples was carried out using DSC 822e (Mettler 
Toledo, Switzerland) equipped with a refrigerated cooling system. Few mg of the samples (2-3 
mg) were placed in an aluminum pans and sealed with a lid. The samples were scanned from 20 
to 200 °C at a rate of 10 °C/min. N2 gas was used as an inert atmosphere at a flow rate of 80 
ml/min. The thermal behaviors of the samples such as onset temperatures, endothermic and 
exothermic enthalpies were determined using the software provided (STARe Ver. 12.00 Mettler 
Toledo, Switzerland). 
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In addition, the Gordon-Taylor equation (equation 1) has been used in order to estimate the 
theoretical Tgmix of samples and compare this value to experimental Tgmix of two components [29].  
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In this equation w1 and w2 are the weight fraction of components 1 and 2. Tg1 and Tg2 is the glass 
transition of two components. ρ is the true density calculated by helium micrometers. The true 
density of amorphous CUR and PVP were determined 1.3 and 1.18 g/cm3 respectively.   
 
2.2.8. X-ray powder diffraction studies (XRPD) 
The solid state of the freeze-dried samples was analyzed using XRPD. Scanning were carried out 
on selected samples using a D8 Advance diffractometer (Bruker, Germany) with Cu Kα radiation 
(λ = 1.54 Å) with scanning range of 5-40° (2Ɵ) with a step size of 0.05. 
 
2.2.9. Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectra were obtained with WQF-510/520 FT-IR spectrophotometer, China. Samples were 
prepared by mixing with potassium bromide (KBr) at a ratio of 1:10 and then compressed with 
hydraulic press at a pressure of 7 tones. The samples were scanned against a blank KBr disk 
ranging from 4000 to 450 cm-1 with a resolution of 1.0 cm-1. 
 
2.2.10. Dissolution studies 
The dissolution properties of curcumin samples were examined using a USP dissolution apparatus 
2, paddle method (Pharmatest, Germany). The dissolution medium was 1000 ml distilled water 
containing 0.25%w/v sodium dodecyl sulfate at 37 °C with the paddles rotation of 50 rpm. Samples 
equivalent to 10 mg of CUR was placed at the top of the dissolution medium. 5 ml of the 
dissolution medium was removed at selected time intervals and replaced by 5 ml fresh dissolution 
medium. Each sample was immediately filtered through 0.22 µm cellulose ester filter (MS® Nylon 
Syringe Filter) and assayed at a wavelength of 426 nm by spectrophotometer (Shimadzu, Japan). 
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The concentration of the solution was then calculated on the basis of a calibration curve obtained 
for CUR at this wavelength. The dissolution test was repeated 3 times for each formulation.  
The dissolution efficiency (DE%) and mean dissolution time (MDT) were determined in order to 
have a better understanding and comparison of dissolution profiles [30]. In equation 2, DE% 
represents the area under the dissolution curve (y) up to a certain time t, expressed as a percentage 
of the area of the rectangle described by 100% dissolution in the same time.  
 
Equation 2 
 
 
Equation 3 represents MDT and it reflects the mean time of dissolution. In equation 3 

t
i defines 
the midpoint of the time period during which the fraction ΔM of the drug has been released from 
sample.  
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2.2.12. Re-dispersibility in water 
In this test simply an excess amount of each freeze-dried samples were put on the surface of 
distilled water in a beaker and then re-dispersion of particles was recorded photographically after 
3 seconds. 
Although the dissolution studies provide suitable results and indirectly show how fast the particles 
could be dispersed and being wet in water, this test has been carried out to illustrate visually and 
supports the dissolution results.  
 
3. Results and discussions  
In this study antisolvent crystallization method was used in order to produce nanoparticles of 
curcumin with high water solubility. In addition, the effect of HPH process on solubility and 
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dissolution rate of CUR was studied. It has been shown  that the combination technology could 
result in smaller particles with narrow size distribution [13, 15, 16]. Moreover, in this study the 
efficiency of PVP-K30 and HPMC E3 as a stabilizer (at various ratios) has been evaluated.  
 
3.1. Morphological analysis  
The optical microscope screening was used in order to monitor the obtained suspensions. For better 
visualization of freeze-dried samples, scanning electron microscopy has been used.  
Figure 1 shows the optical microscope images of freshly obtained suspensions. The freshly 
crystalized CUR obtained in the absence of any stabilizer showed aggregated particles with wide 
particle size distribution at a magnification of ×100 (Fig 1A). According to the hydrophobicity of 
CUR it could be predicted that the generated crystals could aggregate together and the crystals 
become large. This result has also been reported for CUR prepared with antisolvent crystallization 
[31, 32]. Yadav and Kumar reported that curcumin nanocrystals could be prepared by antisolvent 
precipitation however these particles aggregated simply after a while in the absence of any 
stabilizer. These aggregations and then an increase in the particle size did not occur when gelatin 
was used as a stabilizer [32].  
As shown in Figure 1B very small and homogenous particles obtained after crystallization in the 
presence of stabilizers. Both PVP and HPMC at various concentrations showed similar 
morphology (for sake of space only one sample was shown). As described in the introduction 
section in order to produce nanoparticles with smaller particles size HPH was used. Interestingly, 
the samples introduced to HPH, produced suspensions with larger particle size and different shapes 
compared to CRS samples (Figure 1C). These samples showed platy-shape crystals instead of 
spherical particles obtained via CRS method. The formation of spherical particle (Figure 1B) could 
be due to the creation of temporary nanoemulsion droplets (quasi-emulsion) during the 
crystallization that has been reported before for celecoxib in our previous study [17]. When 
temporary nanoemulsions were formed, their structures could be destroyed by a high energy input 
such as HPH process and this in turn can lead to the formation of suspensions with different particle 
morphologies with a wider particle size distribution. Similar results have been reported when  
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antisolvent precipitation technique was used to obtain  celecoxib particles in the presence of d 
PVP-K30 [17].   
The rupture of nanoemulsion droplets could be occurred by freeze drying process. Freeze-dried 
samples are shown in Figure 2. Untreated CUR shows irregular and large particles (Figure 2A) 
while the crystallized sample without usage of a stabilizer (CUR-CRS-FD) showed star-like large 
crystals. It seems during the crystallization process small crystals of CUR (because of its 
hydrophobic nature) aggregated together and become bigger after a while (Figure 2B). The star-
like morphology of CUR prepared with antisolvent crystallization has also been reported and 
discussed elsewhere[31]. Generally, the crystalized samples showed platy-shape particles with 
smaller particle size. Figures 2C and 2D show the freeze dried samples crystallized in the present 
of 5% PVP without and with the employment of HPH process respectively. Both these samples 
exhibited platy-shape crystals and it seems HPH process could not affect the morphology of these 
samples, but as shown in this Figure the particle size of HPH-FD samples (Figure 2D) is smaller 
compared to when HPH was not used. In CUR:HPMC 5% CRS-FD sample some rode-shape 
crystals can be seen which these particles can be broken down to smaller particles and converted 
to platy-shape crystals with smaller particle size (Figure 2F).  
Generally, it seems in freeze-dried samples, HPH process could break down the particles to smaller 
nanoscale particles with platy-shape crystal habit. This morphology could be useful in order to 
improve the dissolution rate due to high surface area available for dissolution.   
 
3.2. Particle size measurement  
Particle size analyses has been performed in order to investigate the effect of stabilizers with 
various concentrations and also the effect of HPH and freeze drying processes on particle size and 
Polydispersity Index (PdI) of the samples.  
As shown in Table 1, the presence of stabilizers at various concentrations generated suspension 
with nanoscale particles. This occurrence demonstrated the beneficial effect of the presence of 
HPMC or PVP-K30 as stabilizer during the crystallization process. There is no significant different 
between the particle size of suspensions obtained with HPMC or PVP (p > 0.05). In addition, there 
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is no significant different between the particle size at various concentrations of the stabilizers (p > 
0.05).  
The results in Table 1 showed that, in general, mean particle size and PdI of CRS samples are 
smaller than formulations obtained via HPH (p < 0.05). As described in the morphology section, 
the nanoemulsion obtained via CRS method could be broken down by HPH process and produce 
the suspensions with larger particle size.  
The mean particle size of all freeze-dried samples are larger than non-freeze-dried samples. It is 
obvious that during freeze drying process the nanoparticles could aggregate together hence re-
dispersion of these particles does not happen easily. It has been reported that the major challenge 
in formulation of pharmaceutical nanoparticles is their instability and aggregation of these nano- 
ranged particles. This phenomenon could be more problematic when the particles separated from 
a suspension and compress into a tablet [33, 34]. Regarding the zeta potential (Table 1) it seems 
that the samples obtained using PVP can be more stable than CUR:HPMC samples. It has been 
proved that in order to make a nanosuspension more stable a minimum zeta potential of ±30 mV 
is required. [35].      
It was interesting to note that CRS samples showed smaller particles size compared to the samples 
obtained via HPH while the HPH-FD samples showed smaller particle size compared to CRS-FD 
samples. Generally, in these samples (HPH-FD) all the samples showed smaller particle size with 
lower PdI compared to similar CRS-FD samples. This phenomenon could be attributed to the 
ability of HPH process in order to separate the particles after being freeze- dried. Several studies 
reported that high pressure homogenizer could produce nanocrystals with narrow PdI with a 
suitable re-dispersibility [5]. 
 
3.3. Determination of saturation solubility  
This analysis was performed in order to investigate the effect of hydrophilic stabilizers and 
methods of preparation on saturation solubility of CUR. The saturation solubility shows that 
untreated CUR exhibited very low saturation solubility (0.18 µg/ml) while the presence of 
hydrophilic stabilizer could enhance the solubility of CUR significantly (p < 0.05). This 
enhancement becomes more pronounced by the presence of higher stabilizer concentration. 
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Comparing all the CRS-FD samples of HPMC and PVP with their physical mixtures (PMs) 
exhibited no significant difference between them, however, in general the PVP showed beneficial 
effect in order to increase the saturation solubility of CUR. This result was exhibited for both CRS-
FD and PMs samples (Figure 3A and 3B). Figure 3 also showed that HPH-FD samples exhibited 
higher saturation solubility compared to CRS-FD and PMs samples and this enhancement is higher 
for PVP samples compared to HPMC samples. Statistical analysis demonstrated that saturation 
solubility of all CUR: PVP HPH-FD samples was higher compared to CRS-FD and PMs samples 
(p < 0.05). This was not the case for CUR:HPMC HPH-FD samples (p > 0.05). In general, it can 
be concluded that antisolvent crystallization technique followed by HPH could increase the 
saturation solubility of CUR with assistance of a stabilizer. In addition, it seems PVP-K30 shows 
a suitable efficiency compared to HPMC in terms of increasing the saturated solubility. It has been 
reported that the selection of an efficient stabilizer for a specific API in antisolvent precipitation 
technique depends on the physicochemical properties of API and stabilizer and there is no 
guarantee a specific stabilizer should work for all APIs with different physicochemical properties 
[12]. 
   
3.4. Differential scanning calorimetry (DSC) 
Thermal analysis usually used to investigate the solid state of materials. Moreover, any interaction 
between API and stabilizer could be determined by this analysis. Figure 4 shows the DSC traces 
of untreated CUR and some selected samples. As shown in Figure 4, untreated CUR shows an 
endothermic peak near 176 °C corresponding to its melting point which reported in literature  [36, 
37]. The crystallized CUR without any stabilizer (CUR-CRS) showed two endothermic peaks near 
162 °C and 157 °C. Comparison of these two thermograms demonstrated the presence of a new 
polymorph of CUR in CUR-CRS samples. In addition, the enthalpy of fusion in 2nd peak of CUR-
CRS sample reduced from 82 J/g for untreated CUR to 74 J/g for newly prepared sample. This 
may be due to a slight reduction in the crystallinity of the sample which also has been reported 
elsewhere for curcumin when antisolvent crystallization was applied [31, 36, 38]. 
PM samples showed a broad melting endothermic peak near melting point of CUR. In these 
samples tailing the peaks to the left and expanding the peaks may be attributed to partial dissolution 
of CUR in stabilizers when it was heated above the Tg of polymers during DSC analysis. This 
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result indicates the possibility of stabilizer/CUR miscibility. Similar results have been reported 
before for many API and polymers [39, 40]. CUR:HPMC 50% CRS-FD sample showed similar 
pattern to its PM sample. It seems in this sample there is no specific interaction between CUR and 
HPMC. The absence of CUR melting endothermic peak in CUR:PVP 50% CRS-FD formulation 
could be an indication of amorphous CUR in this sample. As shown in Figure 4 CUR:PVP 50% 
CRS-FD sample shows small endothermic peak near 148 °C attributed to Tgmix of binary mixture 
of CUR/PVP (this peak is not visible in small scale). According to Gordon-Taylor equation, ideal 
molecular mixing of two component resulted one Tgmix between the Tg of two components [29, 41]. 
The theoretical Tgmix of this binary mixture was calculated 85.5 °C (via equation 1) while the 
experimentally determined Tg of binary mixture obtained near 148 °C (Figure 4). This value is 
higher than the predicted Tgmix and indicates a strong interaction between CUR and PVP and 
confirms the rigidity of molecules in this sample. This positive deviation to higher temperature 
could be due to the intermolecular interaction or possibility of hydrogen bonding between CUR 
and PVP that will discuss in FT-IR study later.   
 
3.5. X-ray powder diffraction studies (XRPD) 
The results of XRPD analysis have been depicted in Figure 5. Untreated CUR showed sharp peaks 
at 2Ɵ values of 9.15°, 10.3°, 14.2°, 16.9°, 20.1° and 21.1° which regarded to its crystalline state 
[36]. CUR-CRS samples showed similar characteristic peaks but with lower peak intensity. This 
result demonstrates lower crystallinity of this sample compared to untreated one. In addition, in 
CUR-CRS sample the presence of a new peak at 16.2° 2Ɵ value indicated the appearance of a new 
polymorph in this sample. These results support the DSC findings and are in agreement with 
previous data [31, 38].  Sanuphi et al proved that the polymorph 2 exhibited lower crystallinity 
compared to polymorph 1 of curcumin [36]. Comparison of XRPD pattern of CUR-CRS to CUR-
HPH exhibited that there is no different between these two samples. It seems HPH process does 
not modify the solid state of CUR during the homogenization process. Both crystalized samples 
containing 5% PVP exhibited similar pattern to the crystallized CUR however a small reduction 
in peak intensities are observed. For example, the intensity of peak at 16.2° 2Ɵ value is reduced. 
By increasing the polymer ratio to curcumin (in this case PVP) the peaks of CUR completely 
diminished, and hallo pattern is exhibited. This result indicated that CUR existed in amorphous 
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state in this sample. It seems presence of high ratio of PVP as stabilizer could penetrate into the 
crystalline structure of CUR and converted the crystalline nature of CUR to amorphous form. This 
result confirmed the DSC finding. As described in DSC study this sample (CUR:PVP 50% CRS-
FD) showed no endothermic peak and instead it exhibited one single Tg as a result of miscibility 
of CUR and PVP (as CUR:PVP 50% CRS-FD and CUR:PVP 50% HPH-FD sample showed 
similar XRPD pattern, therefore, XRPD of one sample shown). As shown in Figure 5, in 
CUR:HPMC 50% HPH-FD sample the intensity of CUR peaks reduced however the peak at 16.2° 
2Ɵ is still visible. As described in DSC analysis it seems in this sample CUR does not present in 
amorphous state although the crystallinity of CUR decreased due to the presence of 50% HPMC 
as a polymer. Previous studies have been shown that the presence of polymer as a stabilizer during 
crystallization can reduce the crystallinity of drugs. This occurrence is due to the covering of 
particles by stabilizer during crystal growth phase of antisolvent precipitation process [16, 17, 21].   
 
3.6. Fourier transform infrared spectroscopy (FT-IR) 
FT-IR study was performed in order to investigate the possibility of hydrogen bonding between 
CUR and stabilizers during antisolvent crystallization. The FT-IR spectrums of untreated 
curcumin, CUR-CRS and crystalized samples prepared with 50% stabilizer were showed in Figure 
6. As reported previous by other researchers, untreated curcumin (form 1) showed characteristic 
peaks at 1601 cm-1 belonged to aromatic C=C stretching, at 1429 cm-1 due to phenolic C-O 
stretching, at 1281 cm-1 due to enolic C-O stretching and a sharp peak at 3505 cm-1 which is 
attributed to OH stretching. In addition, as described in literature  polymorph 1 curcumin shows a 
characteristic peak at 1628 cm-1 corresponded to its carbonyl group [36, 42]. Regularly carbonyl 
stretching band appear at 1700 cm-1 however formation of an intramolecular hydrogen bond leads 
to change of wave number to 1628 cm-1. Resonance-assisted intramolecular hydrogen bond 
stabilized this conformation. It has been reported that this keto-enol tautomerism is the most 
favorable form of curcumin [36, 42]. 
CUR-CRS sample showed the same band at 1628 cm-1 indicating that the intramolecular hydrogen 
bonding keto-enol tautomer existed in this sample too. However, the OH stretching bond has been 
shifted to 3406 cm-1 and 3259 cm-1. Moreover, the C=C aromatic stretching at 1601 cm-1 bifurcated 
to 1601 cm-1 and 1587 cm-1. In addition, the phenolic C-O stretching at 1281 cm-1 bifurcated also 
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to 1281 cm-1 and 1263 cm-1 (Figures 6A and 6B). All these changes demonstrated the formation 
of polymorph 2 CUR that Sanphui et al reported  [36]. These findings are in good agreement with 
DSC and XRPD results.  
As shown in Figure 6, PVP exhibited large and broad spectrum at 1668 cm-1 corresponding to C=O 
stretching vibration. It can be expecting that this group can participate in hydrogen bonding as a 
proton acceptor. In molecular structure of CUR, the possible proton donor could be the phenolic 
OH group. This possible hydrogen bonding should change the wave-number of these groups. The 
changes in OH groups position of CUR to 3406 cm-1  and broadening the peaks might be due to 
the presence of curcumin in amorphous nature [36]. Moreover, the presence of new wave-number 
at 3170 cm-1 could be attributed to the formation of hydrogen bond between CUR and PVP that 
previously reported by Wegiel et al in solid dispersion of CUR and PVP [42]. Due to the large 
number of carbonyl groups of PVP, the change in wave-number of this group is not simply visible. 
This phenomenon is attributed to the large number of unbounded carbonyl group of PVP compared 
to bounded group with OH group of CUR. FT-IR spectrum of CUR:HPMC 50% CRS-FD sample 
did not show any interaction between HPMC and CUR.  
 
3.7. Dissolution studies 
One of the main aims of the current research is dissolution enhancement of CUR. Therefore, 
dissolution studies were performed to investigate the effect of antisolvent crystallization method 
and HPH process on dissolution behavior of CUR. The dissolution behavior of untreated CUR and 
freeze-dried samples are shown in Figure 7. As shown in Figure 7, the untreated CUR shows very 
low dissolution rate even at 0.25% SDS. PMs of CUR with different concentrations of stabilizers 
are shown in Figures 7A and 7B. The dissolution rate of CUR increased by increasing the stabilizer 
ratio (Figure 7). PVP and HPMC as hydrophilic stabilizer could enhance the wettability of 
hydrophobic drugs and accelerate the dissolution rate of CUR. The dissolution properties of CRS-
FD samples are shown in Figures 7C and 7D. In CUR:HPMC CRS-FD samples, the dissolution 
rate of CUR was not affected significantly. However, this was not the case for samples crystalized 
in the presence of PVP (Figure 7D). In these samples the dissolution rate of CUR increased 
compared to its PMs and this enhancement become more pronounced by increasing the PVP 
concentration. It can be concluded that antisolvent crystallization in the presence of PVP could 
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produce particles with high dissolution rate. It seems the effect of PVP as a stabilizer plays a critical 
role on dissolution enhancement of CUR as the same enhancement in the dissolution rate was not 
observed for CUR-CRS-FD sample. On the other hand, the presence of PVP alone is not effective 
enough for dissolution enhancement of CUR as the dissolution rate of CUR did not increase 
sufficiently in its PM samples. In CUR:PVP CRS-FD samples an increase in the dissolution rate 
of curcumin become profound by increasing the PVP concentrations in the formulations. It seems 
the higher ratios of PVP could enhance the wettability of CUR hence facilitates the dissolution of 
curcumin. According to Figure 7D there is no remarkable difference between the dissolution rate 
of CUR:PVP 25% CRS-FD and CUR:PVP 50% CRS-FD samples. These samples showed DE of 
82-83% and MDT of 6-7 min (Table 2). Figures 7E and 7F show the dissolution rate of HPH-FD 
samples. CUR-HPH-FD sample shows higher dissolution rate compared to untreated CUR and 
CUR-CRS-FD samples. Comparing the CUR:HPMC HPH-FD with CUR:HPMC CRS-FD 
samples shows that HPH technique could enhance the dissolution rate of CUR effectively. For 
instance, more than 80% of curcumin was released within 30 min from CUR:HPMC 25% HPH-
FD sample while this value is lower than 30% for CUR:HPMC 25% CRS-FD sample. This 
enhancement in the percentage of dissolution of curcumin could be attributed to the presence of 
smaller particle size in these samples. According to the results of particle size analysis (Table 1) 
and SEM images (Figure 2), the HPH-FD samples exhibited smaller particle size and PdI 
compared to CRS-FD sample. For samples prepared with PVP as a stabilizer similar results were 
obtained. Comparing the Figures 7F and 7D show that HPH process enhanced the dissolution rate 
of almost all samples. This enhancement is more pronounced for samples prepared with lower 
PVP concentrations. According to Table 2 the amount of DE% and MDT for samples prepared 
with 25% and 50% PVP is almost similar to CRS-FD and HPH-FD formulations, while this 
similarity does not exist for the samples prepared with lower PVP concentration (5% and 10%). 
For example, in CUR:PVP 5% HPH-FD sample near 70% of CUR released after 10 min while this 
value is about 23% for CUR:PVP 5% CRS-FD sample. According to the results of particle size 
analysis and SEM images the HPH-FD samples exhibited smaller particle size and PdI compared 
to CRS-FD ones (similar to HPMC samples). Although the particle size is one of the most 
important parameters to control the dissolution rate and solubility of drugs however the effect of 
hydrophilic stabilizer (PVP in this case) should not be ignored. In other word, in the sample contain 
higher PVP percentage the effect of hydrophilic stabilizer controls the dissolution rate while in 
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sample containing smaller ratio of PVP (5 and 10%) particle size plays a critical role on dissolution 
profile of CUR. In addition, according to DSC and XRPD studies sample prepared with 50% PVP 
contain amorphous CUR and simultaneously generated CUR/PVP matrix with a single Tg (Figure 
4). Moreover, in this sample amorphous CUR participates in hydrogen bonding with PVP (Figure 
6). All these findings justify the high dissolution rate and saturation solubility of CUR in 
crystalized samples contain 50% PVP. The higher solubility and dissolution rate of amorphous 
CUR compared to its crystalline form has been reported [36, 43]. Therefore, the effect of particle 
size is not determinative in samples crystallized in the presence of 50% PVP.  
 
3.8. Re-dispersibility in water 
This simple test has been performed to assess the dispersion of powders in water (as a first step of 
dissolution and finally absorption in the gastrointestinal tract) visually. In this test re-dispersion of 
samples recorded by digital camera after 3 second from placing a specified amount of powder on 
the surface of distilled water in a beaker. As shown in Figure 8A, untreated CUR does not disperse 
in water due to high hydrophobic nature, however in HPH-FD samples re-dispersion of particles 
occurred better. In samples prepared with 5% stabilizer (both PVP and HPMC) similar result was 
obtained. This phenomenon could be attributed to the presence of smaller particle size in HPH-FD 
samples. The results of this study are in good agreement with dissolution analysis. It has already 
been reported that nanoparticles prepared with high pressure homogenizer could re-disperse in 
water desirably [5].   
 
4. Conclusion 
It can be concluded that antisolvent crystallization followed by high pressure homogenization 
could be a useful procedure to prepare nanoparticles of curcumin with higher dissolution and 
saturation solubility. Using a suitable stabilizer plays a critical role on dissolution enhancement of 
curcumin during antisolvent crystallization. PVP as a stabilizer is able to inhibit the growth of 
particles during antisolvent crystallization technique. PVP can participate in hydrogen bonding 
with curcumin and reduces the crystallinity of curcumin. Formulation containing high 
concentration of PVP showed high dissolution rate even without using high pressure 
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homogenization process. However, using high pressure homogenizer may help formulator prepare 
samples with low concentrations of PVP without compromising its dissolution rate. The results of 
this study showed that particle size, solid state of curcumin, presence of stabilizer, interaction of 
curcumin with stabilizers and in general physicochemical properties of samples play a critical role 
on dissolution rate of curcumin as well.   
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Fig 1. Optical microscope image of (A) curcumin obtained from anti solvent crystallization (CUR-CRS), 
(B) curcumin obtained from anti solvent crystallization at presence of 5% stabilizer, (C) curcumin 
obtained from anti solvent crystallization followed by high pressure homogenization at presence of 5% 
stabilizer.   
 
Fig 2. SEM image of (A) untreated curcumin, (B) CRS-FD samples without stabilizer, (C) CRS-FD 
samples with 5% PVP, (D) HPH-FD samples with 5% PVP, (E) CRS-FD samples with 5% HPMC, (F) 
HPH-FD samples with 5% HPMC. 
 
Fig 3. Saturation solubility of untreated curcumin, samples prepared with physical mixture (PM), freeze-
dried samples prepared by antisolvent crystallization (CRS-FD) and freeze dried samples prepared by 
antisolvent crystallization followed by high pressure homogenization (HPH-FD). 
 
Fig4. DSC traces of pure CUR, physical mixture (PM), freeze-dried samples prepared by antisolvent 
crystallization (CUR-CRS-FD) and freeze-dried samples prepared by antisolvent crystallization in the 
presence of 50% of PVP or HPMC. 
 
Fig 5. XRPD pattern of untreated CUR, samples prepared by antisolvent crystallization (CRS-FD) and 
samples prepared by antisolvent crystallization followed by high pressure homogenization (HPH-FD) in 
the presence of stabilizer. 
 
Fig 6. FT-IR spectra of untreated CUR, freeze-dried samples obtained through antisolvent crystallization 
techniques (CRS) in the presence of 50% PVP or HPMC. 
 
Fig 7. Dissolution profiles for different samples: (A, B) physical mixtures of CUR and stabilizers, (C, D) 
freeze-dried samples prepared by antisolvent crystallization with carriers, (E, F) freeze-dried samples 
prepared by antisolvent crystallization followed by high pressure homogenization of CUR and stabilizers 
(HPH-FD). (n = 3, and error bars are standard deviation). 
 
Fig 8. Re-dispersion of different samples in distilled water. (A) without stabilizers, (B) with 5% HPMC, 
(C) with 5% PVP.  
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Table 1. Particle size of untreated CUR and CUR:HPMC/PVP samples prepared by different procedures. 
antisolvent crystallization (CRS), antisolvent crystallization followed by high pressure homogenization 
(HPH). Freeze dried antisolvent crystallization (CRS-FD), freeze dried antisolvent crystallization followed 
by high pressure homogenization (HPH-FD). 
  
 
 
  
Sample size 
CRS 
PdI Zeta-
potential 
size 
HPH 
PdI size CRS 
FD 
PdI size 
HPH 
FD 
PdI 
CUR ND ND ND ND ND ND ND ND ND 
PVP 5% 272 ± 
40 
0.172 ± 
0.041 
-29 790 ± 
32 
0.425 ± 
0.016 
2748 ± 
1251 
1 706 ± 
452 
0.562 ± 
0.098 
PVP 
10% 
186 ± 
16 
0.258 ± 
0.053 
-24 532 ± 
37 
0.377 ± 
0.021 
3018 ± 
825 
0.982 ± 
0.271 
1073 ± 
349 
0.405 ± 
0.102 
PVP 
25% 
231 ± 
38 
0.176 ± 
0.044 
-33 439 ± 
64 
0.463 ± 
0.082 
3447 ± 
317 
0.856 ± 
0.198 
1024 ± 
441 
0.595 ± 
0.097 
PVP 
50% 
259 ± 
21 
0.161 ± 
0.037 
-25 563 ± 
91 
0.193 ± 
0.022 
2193 ± 
290 
0.597 ± 
0.102 
915 ± 
398 
0.715 ± 
0.136 
HPMC 
5% 
222 ± 
13 
0.425 ± 
0.041 
-24 1631 
± 84 
0.844 ± 
0.092 
3224 ± 
834 
1 2101 ± 
1201 
0.892 ± 
0.201 
HPMC 
10% 
201 ± 
13 
0.377 ± 
0.052 
-25 599 ± 
37 
0.353 ± 
0.028 
2663 ± 
650 
0.968 ± 
0.195 
1512 ± 
825 
0.687 ± 
0.085 
HPMC 
25% 
197 ± 
11 
0.463 ± 
0.037 
-18 594 ± 
49 
0.488 ± 
0.017 
4374 ± 
321 
1 1389 ± 
768 
0.725 ± 
0.091 
HPMC 
50% 
210 ± 
14 
0.193 ± 
0.021 
-13 1244 
± 91 
0.456 ± 
0.029 
2266 ± 
345 
0.416 ± 
0.189 
1225 ± 
504 
0.521 ± 
0.234 
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Table 2. Dissolution efficiency (DE) and mean dissolution time (MDT) of untreated CUR and 
CUR:HPMC/PVP samples prepared with physical mixture (PM), antisolvent crystallization (CRS) and 
crystallization followed by high pressure homogenization (HPH). 
 
Samples DE40 % MDT 
(min) 
Samples DE40 % MDT 
(min) 
CUR 7.81 19.38 CUR 7.81 19.38 
CUR CRS-FD 10.93 16.16 CUR CRS-FD 10.93 16.16 
CUR HPH-FD 14.34 15.44 CUR HPH-FD 14.34 15.44 
HPMC 5% PM 12.67 11.77 PVP 5% PM 11.33 17.92 
HPMC 10% PM 16.87 8.55 PVP 10% PM 23.85 6.84 
HPMC 25% PM 17.82 11.96 PVP 25% PM 13.91 8.81 
HPMC 50% PM 22.10 10.85 PVP 50% PM 22.96 10.49 
HPMC 5% CRS-FD 23.82 8.19 PVP 5% CRS-FD 30.48 13.60 
HPMC 10% CRS-FD 23.72 9.16 PVP 10% CRS-FD 64.62 5.71 
HPMC 25% CRS-FD 24.33 9.67 PVP 25% CRS-FD 81.91 6.99 
HPMC 50% CRS-FD 27.23 8.57 PVP 50% CRS-FD 82.58 6.16 
HPMC 5% HPH-FD 49.77 11.80 PVP 5% HPH-FD 71.98 8.92 
HPMC 10% HPH-FD 54.06 11.28 PVP 10% HPH-FD 78.93 6.45 
HPMC 25% HPH-FD 72.44 5.44 PVP 25% HPH-FD 78.26 7.38 
HPMC 50% HPH-FD 72.24 6.42 PVP 50% HPH-FD 78.22 7.91 
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Highlights 
 Curcumin nanoparticles were prepared by antisolvent crystallization and high 
pressure homogenization. 
 
 The curcumin crystallized in the absence of stabilizer showed different 
polymorphic form for curcumin. 
 
 The Presence of stabilizer and using high pressure homogenization improved 
the solubility of curcumin. 
 
 High concentration of PVP produced amorphous curcumin nanoparticles. 
 
 The samples prepared with high pressure homogenizer using 50% PVP 
showed 25-fold higher solubility compared to untreated curcumin. 
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